
S4-32 – Drug Development Stories from EASL and ADA: Part 1
Stephen Harrison and Jörn Schattenberg join Roger Green to discuss newly released Phase 3 MAESTRO-NASH data on resmetirom and the wider NASH therapeutic landscape, AI-assisted digital pathology, what the field understands about liver volume reduction, an increasing burden of cirrhosis and much more. This episode is packed with robust analysis and insights stemming from a busy past month at the EASL Congress and ADA Scientific Sessions meetings.








